人们以往大多只关注由敏感细菌通过基因水平转移和自发突变方式获得的耐药性,而忽略了细菌对某类抗生素天然耐药的重要特性,细菌的这种特性又被称为固有耐药。固有耐药由固有耐药基因决定,这类基因是指存在于某类细菌染色体上位置保守的与耐药相关的一类基因。近年来,对固有耐药基因的研究已经越来越受到重视。固有耐药基因的发现不仅可以为新药研制提供药物作用靶标,而且通过阻断病原菌固有耐药基因还可使以往对该类菌不起作用的抗生素药物重新焕发抗菌活性。此外,已有研究表明固有耐药基因能够被移动元件捕获进而可水平转移至其他细菌,因此通过监测固有耐药基因可以预测耐药菌的出现。本文对传统的细菌固有耐药机制包括细胞膜的低渗透性和多药外排泵系统,以及已知重要病原菌的转移酶和代谢相关酶的固有耐药机制进行了介绍。同时,进一步对隐性固有耐药基因的特性进行了阐释,最后探讨了固有耐药与获得性耐药的进化关系,指出固有耐药基因很可能是一些获得性耐药基因的来源。
Antibiotic resistance is often considered to be a trait acquired by previously susceptible bacteria, on the basis of which can be attributed to the horizontal acquisition of new genes or the occurrence of spontaneous mutation. In addition to acquired resistance, bacteria have a trait of intrinsic resistance to different classes of antibiotics. An intrinsic resistance gene is involved in intrinsic resistance, and its presence in bacterial strains is independent of previous antibiotic exposure and is not caused by horizontal gene transfer. Recently, interest in intrinsic resistance genes has increased, because these gene products not only may provide attractive therapeutic targets for development of novel drugs that rejuvenate the activity of existing antibiotics, and but also might predict future emergence of resistant pathogens if they become mobilized. In the present review, we summarize the conventional examples of intrinsic resistance, including the impermeability of cellular envelopes, the activity of multidrug efflux pumps or lack of drug targets. We also demonstrate that transferases and enzymes involved in basic bacterial metabolic processes confer intrinsic resistance in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. We present as well information on the cryptic intrinsic resistance genes that do not confer resistance to their native hosts but are capable of conferring resistance when their expression levels are increased and the activation of the cryptic genes. Finally, we discuss that intrinsic genes could be the origin of acquired resistance, especially in the genus Acinetobacter.
[1] Neu HC. The crisis in antibiotic resistance. Science , 1992, 257(5073): 1064-1073.
[2] Lv JY, Qu F. Multidrug-resistant microorganism and prevention measures. Beijing: People's Military Medical Press. 2011. 吕吉云, 曲芬. 多重耐药微生物及防治对策. 北京: 人民军医出版社, 2011.
[3] WHO. Antimicrobial resistance: global report on surveillance. Geneva: WHO, 2014.
[4] Cox G, Wright GD. Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions. Int J Med Microbiol , 2013, 303(6-7): 287-292.
[5] Fajardo A, Martínez-Martín N, Mercadillo M, Galán JC, Ghysels B, Matthijs S, Cornelis P, Wiehlmann L, Tümmler B, Baquero F, Martínez JL. The neglected intrinsic resistome of bacterial pathogens. PLoS One , 2008, 3(2): e1619.
[6] Olivares J, Bernardini A, Garcia-Leon G, Corona F, Sanchez MB, Martinez JL. The intrinsic resistome of bacterial pathogens. Front Microbiol , 2013, 4: 103.
[7] Perry JA, Westman EL, Wright GD. The antibiotic resistome: what's new?. Curr Opin Microbiol , 2014, 21: 45-50.
[8] Yoon EJ, Goussard S, Touchon M, Krizova L, Cerqueira G, Murphy C, Lambert T, Grillot-Courvalin C, Nemec A, Courvalin P. Origin in Acinetobacter guillouiae and dissemination of the aminoglycoside-modifying enzyme Aph (3')-VI. mBio , 2014, 5(5): e01972-14.
[9] Yoon EJ, Goussard S, Nemec A, Lambert T, Courvalin P, Grillot-Courvalin C. Origin in Acinetobacter gyllenbergii and dissemination of aminoglycoside-modifying enzyme AAC(6')-Ih. J Antimicrob Chemother , 2016, 71(3): 601- 606.
[10] Nikaido H, Nikaido K, Harayama S. Identification and characterization of porins in Pseudomonas aeruginosa . J Biol Chem , 1991, 266(2): 770-779.
[11] Fernández L, Hancock REW. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev , 2012, 25(4): 661-681.
[12] Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa : clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev , 2009, 22(4): 582-610.
[13] Nikaido H. Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin Cell Dev Biol , 2001, 12(3): 215-223.
[14] Nikaido H. The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access?. Drug Resist Updat , 1998, 1(2): 93-98.
[15] Lee A, Mao WM, Warren MS, Mistry A, Hoshino K, Okumura R, Ishida H, Lomovskaya O. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol , 2000, 182(11): 3142-3150.
[16] Paul S, Alegre KO, Holdsworth SR, Rice M, Brown JA, McVeigh P, Kelly SM, Law CJ. A single-component multidrug transporter of the major facilitator superfamily is part of a network that protects Escherichia coli from bile salt stress. Mol Microbiol , 2014, 92(4): 872-884.
[17] Tikhonova EB, Wang QJ, Zgurskaya HI. Chimeric analysis of the multicomponent multidrug efflux transporters from gram-negative bacteria. J Bacteriol , 2002, 184(23): 6499-6507.
[18] Sulavik MC, Houseweart C, Cramer C, Jiwani N, Murgolo N, Greene J, DiDomenico B, Shaw KJ, Miller GH, Hare R, Shimer G. Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother , 2001, 45(4): 1126-1136.
[19] Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa . Clin Infect Dis , 2006, 43 (Suppl. 2): S100-S105.
[20] Perreten V, Schwarz FV, Teuber M, Levy SB. Mdt(A), a new efflux protein conferring multiple antibiotic resistance in Lactococcus lactis and Escherichia coli . Antimicrob Agents Chemother , 2001, 45(4): 1109-1114.
[21] Blanc V, Salah-Bey K, Folcher M, Thompson CJ. Molecular characterization and transcriptional analysis of a multidrug resistance gene
